Physician profile
William J Dailey
NPI 1144314642
$11,623.57
in general payments reported to CMS, 2019-2025
58 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,338 · 2021: $1,766 · 2022: $1,595 · 2023: $1,794 · 2024: $2,032 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,409 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,409.32 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.40 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,070.84 | 2019-2025 | |
| Novo Nordisk INC | $924.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $766.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $729.26 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $646.65 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $629.49 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $583.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $435.67 | 2019-2025 | Spravato |
| Abbott Laboratories | $363.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $346.02 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $342.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.40 | 2019-2025 | Jardiance, Trijardy Xr, Synjardy |
| Amgen INC. | $311.58 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $266.09 | 2021-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.